首页 | 本学科首页   官方微博 | 高级检索  
     

不纯性心动过速性心肌病患者的临床特点分析
引用本文:钱海燕,黄觊,杨跃进,杨艳敏,张朝阳,李志忠,张京梅. 不纯性心动过速性心肌病患者的临床特点分析[J]. 中国医药, 2013, 8(2): 145-147
作者姓名:钱海燕  黄觊  杨跃进  杨艳敏  张朝阳  李志忠  张京梅
作者单位:1. 100037,中国医学科学院北京协和医学院 国家心血管病中心 阜外心血管病医院 心血管疾病国家重点实验室 冠心病诊治中心
2. 首都医科大学附属北京安贞医院心内科十五病房
3. 100037,中国医学科学院北京协和医学院 国家心血管病中心 阜外心血管病医院 急诊科、胸痛中心
基金项目:国家自然科学基金资助项目,北京市科技新星计划
摘    要:目的总结不纯性心动过速性心肌病(iTCM)患者的临床特点和预后。方法选择2003年至2011年门诊或住院iTCM患者57例作为研究组,回顾性分析其首诊和随访时临床资料,总结分析其基本特点和预后。选择扩张型心肌病(DCM)患者70例作为对照组。结果研究组治疗后心率[(77±30)次/min比(138±42)7R/min]、N末端B型利钠肽原(NT—ProBNP)[(705±103)ng/L比(5423±1017)ng/L]、左心室舒张末内径(LVDd)[(53±8)mm比(62±16)mm]、左心室射血分数(LVEF)[(58±10)%比(39±14)%]均得到明显的改善(P〈0.05或P〈0.01),对照组治疗后心率[(81±18)次/min比(924-20)次/min]、NT—ProBNP[(12704-320)ng/L比(6705±1300)ng/LI、LVDdl(584-11)mm比(64±15)min]、LVEFI(42±11)%比(38±13)%]亦较治疗前有明显改善(P〈0.05或P〈0.01)。研究组NT—ProBNP、LVDd、LVEF优于对照组,差异均有统计学意义(均P〈0.01)。治疗前研究组NYHAm-Ⅳ级49例(86.0%0),治疗后为5例(8.8%);对照组分别为59例(84.3%)、14例(20.0%),研究组心功能改善程度优于对照组(P〈0.01)。随访时研究组出现复合终点事件者9例(15.8%),而对照组为27例(38.6%),对照组复合终点事件发生率明显高于研究组(P〈0.01)。结论即使存在基础心脏病,当合并快速性心律失常和心力衰竭时,要注意iTCM的诊断。射频消融术或药物可使绝大多数iTCM患者心脏结构和功能显著改善,预后显著优于DCM。

关 键 词:心动过速性心肌病  心律失常  心肌病  扩张型

Clinical characteristics of impure tachycardia-induced cardiomyopathy patients
QIAN Hai-yan , HUANG Ji , YANG Yue-jin , YANG Yan-min , ZHANG Chao-yang , LI Zhi-zhong , ZHANG Jing-mei. Clinical characteristics of impure tachycardia-induced cardiomyopathy patients[J]. China Medicine, 2013, 8(2): 145-147
Authors:QIAN Hai-yan    HUANG Ji    YANG Yue-jin    YANG Yan-min    ZHANG Chao-yang    LI Zhi-zhong    ZHANG Jing-mei
Affiliation:. Center for Coronary Heart Disease, Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
Abstract:Objective To analyze the characteristics and prognosis of impure tachycardia-induced cardio- myopathy (iTCM). Methods All 57 iTCM patients who were admitted in hospital from 2003 to 2011 were assigned to the research group, and 70 dilated cardiomyopathy patients (DCM) were as a control group. Results After the treatment, heart rate, N-terminal pro-B-type natriuretic peptide original (NT-ProBNP), left ventricular end-diastolic diameter ( LVDd), left ventricular ejection fraction in research group were all improved [ ( 77 ± 30) times/min vs ( 138 ± 42) times/min, (705 ± 103 ) ng/L vs (5423± 1017) ng/L, (53 ± 8) mm vs (62 ± 16) mm, ( 58 ± 10) % vs (39 ± 14) % , respectively, P 〈0.05 or P 〈0.01 ]. Heart rate, NT-ProBNP, LVDd, left ventricular ejection fraction in control group were also improved [ ( 81 ±- 18 ) times/rain vs ( 92 ± 20 ) times/rain, ( 1270 ±320 ) ng/L vs (6750±1300)ng/L, (58±11)mmvs (64±15)mm, (42±11)% vs (38±13)%, respectively, P〈0.05 or P 〈0.01 ]. At follow-up, 9 eases (15.8%) composite endpoints were observed in research group, which were lower than that in control group [ 38.6% (27/70), P 〈 0.01 ]. Conclusion After arrhythmia is controlled, the heart structure and function can be improved remarkably in iTCM patients, showing a better prognosis than that in DCM patients.
Keywords:Tachycardia-induced cardiomyopathy  Arrhythmia  Cardiomyopathy,dilated
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号